Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers July 24, 2017
Pharmacy Choice - Pharmaceutical News - Mylan Launches Generic Trilafon Tablets - July 24, 2017

Pharmacy News Article

 4/20/17 - Mylan Launches Generic Trilafon Tablets

HERTFORDSHIRE, England and PITTSBURGH, April 20, 2017 /PRNewswire/ Mylan N.V. (NASDAQ, TASE: MYL), today announced the U.S. launch of Perphenazine Tablets USP, 2 mg, 4 mg, 8 mg and 16 mg, a generic version of the reference listed drug, Trilafon Tablets 2 mg, 4 mg, 8 mg and 16 mg, originally marketed by Schering. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is used in the treatment of schizophrenia and for the control of severe nausea and vomiting in adults. (1)

Perphenazine Tablets USP, 2 mg, 4 mg, 8 mg, and 16 mg, had U.S. sales of approximately $41 million for the 12 months ending Feb. 28, 2017, according to IMS Health.

Currently, Mylan has 236 ANDAs pending FDA approval representing approximately $104.3 billion in annual brand sales, according to IMS Health. Forty-six of these pending ANDAs are potential first-to-file opportunities, representing $42.7 billion in annual brand sales, for the 12 months ending Dec. 31, 2016, according to IMS Health.

Mylan is a global pharmaceutical company committed to setting new standards in healthcare. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of approximately 7,500 marketed products around the world, including antiretroviral therapies on which approximately 50% of people being treated for HIV/AIDS in the developing world depend. We market our products in more than 165 countries and territories. We are one of the world's largest producers of active pharmaceutical ingredients. Every member of our more than 35,000-strong workforce is dedicated to creating better health for a better world, one person at a time. Learn more at mylan.com.

(1) Patients with dementia-related psychosis who are treated with antipsychotic drugs are at an increased risk of death as shown in short-term controlled trials. The deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g. pneumonia) in nature. This drug is not approved for the treatment of patients with dementia-related psychosis.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/mylan-launches-generic-trilafon-tablets-300442893.html

SOURCE Mylan N.V.




Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

LIVE ONLINE CE

Last Chance
Jul 24: What's New? New Treatments for Type 2 Diabetes
Jul 26: Management of Schizophrenia & Acute Agitation
Jul 27: On the Move: A Comprehensive Review of Osteoarthritis, Gout & Rheumatoid Arthritis
Jul 31: Obesity Management: Overview of Pharmacotherapy
Aug 01: Treatment of Depression and Anxiety in Older Adults
Click for entire Webinar Calendar

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.



Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415